FilingSEC EDGAR8-K
Mereo BioPharma Group Granted Additional Compliance Period to Maintain Nasdaq Listing
· SEC accepted
Stagecompliance
Filing content
The company was granted an additional 180-day period until February 16, 2027, to regain compliance with Nasdaq's minimum bid price requirement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…